Fridley, Minn.-based Medtronic’s Adapt-PD trial is evaluating the safety and efficacy of aDBS in patients with Parkinson’s Disease, according to a news release. If approved, aDBS could be enabled as an investigational feature of the Percept PC device for providing the automated adjustment of brain stimulation in the therapeutic management of the symptoms of Parkinson’s Disease, Medtronic said.
The study is slated to take place across 12 sites in the U.S., Europe and Canada, with 36 subjects to undergo an evaluation period of 15 months. The primary endpoint will compare standard continuous DBS to aDBS for hours of “on” time without troublesome dyskinesias.
Stanford University Department of Neurology and Neurological Sciences professor Dr. Helen Bronte-Stewart is the principal investigator in the study and enrolled the first patient at the Stanford Movement Disorders Center.
“Percept PC was developed with a significant amount of capabilities built into its system. We see this technology evolving to deliver even more value over time. The recently initiated ADAPT-PD is the first trial to gather clinical evidence to unlock those capabilities,” Medtronic VP & GM of its brain modulation business Mike Daly said in the release. “Additionally, stimulation adjusted based on patient need, aDBS, could reduce total power output and possibly extend the life of the device.”